EZH2 and cancer: In addition, inhibition of EZH2 by Tazestat or GSK126 can lead to the synthetic lethality of SMARCA4, SMARCB1, PBRM1, and other SWI/SNF chromatin remodeling complex subunit-deficient cancers [94–97].